The European landscape has seen a fascinating evolution in the view of psychedelics. Recently stigmatized, these substances have begun to gain traction for their potential therapeutic applications. From Germany, where clinical trials are underway, to the Italy, where public discourse is expanding, Europe stands out in this re-evaluation of copyrigh